Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist, the next breakthrough for obesity
however, endpoint assessments were not conducted during telephone visits
Head-to-Head Efficacy: Tirzepatide Wins 22% vs 15% Weight Loss The most robust head-to-head comparison comes from the SURPASS-2 trial, a 40-week, phase 3 study of 1,879 adults with type 2 diabetes, published in the N Engl J Med
Cancer (02:03:28) Mind-Body, Mediation, Breathwork (02:07:30) Atrial Fibrillation, Synovial Sarcoma, Heart (02:14:22) Gratitude & Anger
Caloric Restriction (00:08:36) Intermittent Fasting, Growth Hormone, IGF-1 (00:11:05) Hormones & Sleep, Growth Hormone, Menopause, Andropause, TRT (00:13:28) Testosterone & Women, SHGB (00:15:19) Sponsor: Maui Nui (00:16:34) Dihydrotestosterone (DHT), Androgens
Gabapentin (Neurontin)